IL17A and cancer: Additionally, the COVID-19 mRNA vaccines elicit elevated concentrations of interleukin-17 (IL-17) and upregulation of Th17, thereby disrupting Th1-Th2 immunity, escalating the chronic inflammatory condition of cancer patients, and further amplifying tumor growth and progression [220-222].